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Cardioprotective effect of succinate 
dehydrogenase inhibition in rat 
hearts and human myocardium 
with and without diabetes mellitus
Nichlas Riise Jespersen1 ✉, Marie Vognstoft Hjortbak1, Thomas Ravn Lassen1, 
Nicolaj Brejnholt Støttrup1, Jacob Johnsen1, Pernille Tilma tonnesen1, Steen Larsen2,3, Hans-
Henrik Kimose4 & Hans Erik Bøtker1
Ischemia reperfusion (IR) injury may be attenuated through succinate dehydrogenase (SDH) inhibition 
by dimethyl malonate (DiMAL). Whether SDH inhibition yields protection in diabetic individuals and 
translates into human cardiac tissue remain unknown. In isolated perfused hearts from 24 weeks old 
male Zucker diabetic fatty (ZDF) and age matched non-diabetic control rats and atrial trabeculae 
from patients with and without diabetes, we compared infarct size, contractile force recovery and 
mitochondrial function. The cardioprotective effect of a 10 minutes DiMAL administration prior to 
global ischemia and ischemic preconditioning (IPC) was evaluated. In non-diabetic hearts exposed to 
IR, DiMAL 0.1 mM reduced infarct size compared to IR (55 ± 7% vs. 69 ± 6%, p < 0.05). Mitochondrial 
respiration was reduced by DiMAL 0.6 mM compared to sham and DiMAL 0.1 mM (p < 0.05). In 
diabetic hearts an increased concentration of DiMAL (0.6 mM) was required for protection compared 
to IR (64 ± 13% vs. 79 ± 8%, p < 0.05). Mitochondrial function remained unchanged. In trabeculae 
from humans without diabetes, IPC and DiMAL improved contractile force recovery compared to 
IR (43 ± 12% and 43 ± 13% vs. 23 ± 13%, p < 0.05) but in patients with diabetes only IPC provided 
protection compared to IR (51 ± 15% vs. 21 ± 8%, p < 0.05). Neither IPC nor DiMAL modulated 
mitochondrial respiration in patients. Cardioprotection by SDH inhibition is possible in human tissue, 
but depends on diabetes status. The narrow therapeutic range and discrepancy in respiration between 
experimental and human studies may limit clinical translation.
Attenuation of ischemia reperfusion (IR) injury is fundamental for reducing mortality and morbidity in patients 
suffering from a myocardial infarction. Ischemic and pharmacological conditioning strategies, as a supplement to 
revascularization, may reduce IR injury1 by ultimately modulating mitochondrial function2. While experimental 
and clinical conditioning studies have shown compelling evidence of infarct size reduction3,4, translation into 
a clinical benefit has been challenging5,6. Clinical outcome in patients with ST-elevation myocardial infarction 
(STEMI) undergoing immediate revascularization has improved significantly7. However, the development seems 
to level out signifying a continuous need for new cardioprotective strategies that go beyond current conditioning 
modalities in a translational perspective8.
During ischemia, hypoxia leads to suppression of the mitochondrial oxidative phosphorylation (OXPHOS)9. 
Revascularization causes a rapid re-establishment of oxygen and consequently mitochondrial OXPHOS. This 
results in a burst of reactive oxygen species (ROS) emission originating predominantly from complex I in the 
electron transport chain10,11. Succinate increases the complex II (the succinate dehydrogenase (SDH)) linked 
respiration, which seems to overload the capacity of the electron transport system (ETS), and induce reverse 
electron transport to complex I and increased ROS production11. Increased level of ROS, in combination with 
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mitochondrial damage and dysfunction, initiates a vicious circle of increased mitochondrial dysfunction and 
further ROS production ultimately causing myocyte death and irreversible myocardial damage12.
Mitochondrial metabolism can be modulated to reduce excessive ROS production and limit the myocardial 
injury13–15. Inhibition of the malate aspartate shuttle (MAS) (transport of redox compounds from the cytosol into 
the mitochondria) protects the myocardium through reduced succinate accumulation and attenuated ROS medi-
ated mitochondrial dysfunction16. As SDH is the key enzyme responsible for succinate build-up during ischemia, 
inhibition of the SDH represents a more targeted approach to reduce succinate levels during ischemia and rep-
erfusion than inhibition of the MAS. Inhibition of SDH protects against IR injury in cardiomyocytes11. Studies 
examining the cardioprotective capacities of SDH inhibition have been conducted in young healthy, non-diabetic 
animals, so the clinical perspectives of SDH inhibition remain limited.
In patients with diabetes, the outcome following an acute myocardial infarction is impaired compared to 
patients without diabetes17. Compromised outcome in diabetes may be due to metabolic disarrays in the cardiac 
cells beyond the vascular disease burden18,19. Diabetes is associated with mitochondrial dysfunction20, even when 
compared to overweight non-diabetic controls21. Additionally, susceptibility to ischemia is impacted by progres-
sion of the disease with increased injury in mature diabetes22 and the stimulus required for protection increases 
with duration and severity of the disease23. We hypothesized that hearts from mature diabetic individuals have 
alterations in mitochondrial metabolism leading to mitochondrial dysfunction and an inability to achieve pro-
tection by inhibition of the SDH.
We evaluated cardioprotection by pre-ischemic inhibition of the SDH by dimethyl malonate (DiMAL) in 
animals with or without type 2 diabetes. We transferred these findings into human cardiac tissue by examining 
the effect of pre-ischemic SDH inhibition by DiMAL on contractile force recovery and mitochondrial function in 
trabeculae from patients with or without type 2 diabetes.
Methods
Ethical approval. The isolated rat heart study conformed to the Danish law for animal research (Act. No. 
1306 of 23/11/2007, Danish Ministry of Justice) and the guidelines from Guide for the Care and Use of Laboratory 
Animals publishes by the US National Institutes of Health (NIH Publication No. 85–23, revised 1996). The Danish 
Animal Experimental Inspectorate approved the experimental work (Authorization No. 2018-15-0201-01446). 
The human study conformed to the Danish law for clinical studies and the study was approved by the Danish 
health research ethical committee (Authorization No. 1-10-72-361-15) and registered on clinicaltrials.gov (reg-
istration number: NCT02993484). Informed consent was obtained from all participating patients prior to enroll-
ment in the study.
Biological material. We used 24 weeks old male Zucker diabetic fatty (ZDF) rats (homozygote (fa/fa), 
n = 57, approximately 400 g, Charles River Laboratories, USA) and age matched non-diabetic controls (heterozy-
gote (fa/+) n = 59, approximately 400 g, Charles River Laboratories, USA) as a model of mature type 2 diabetes 
following guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection24,25. Due 
to excessive food intake the animals developed mature diabetes at 24 weeks of age. Animals were kept at a con-
stant temperature of 23 °C with a 12 hours light-dark cycle and allowed unlimited access to enriched food (Purina 
5008; recommended by supplier) and water. No anti-diabetic treatment was given. Rats were fasted 10–12 hours 
prior to the experiments in order to allow correct measurement of fasting blood glucose levels22.
We obtained human cardiac atrial appendage tissue from patients undergoing elective coronary artery bypass 
grafting (CABG) or valve replacement surgery with the use of extracorporeal circulation. The right atrial append-
age was removed to allow insertion of the venous tube into the heart. Following excision of the appendage it 
was immediately immerged in oxygenated KH buffer (pH 7.35–7.45, room temperature) and transported to the 
laboratory within 5 minutes.
Study design. In the isolated rat heart study, isolated perfused hearts were divided into 4 groups based on 
the type of interventions (n = 7–9 in each group): (I) Sham hearts (Sham group), (II) IR-injured hearts (IR group) 
and IR-injured hearts co-perfused with (III) 0.1 mM DiMAL or (IV) 0.6 mM DiMAL for 10 minutes prior to 
global no-flow ischemia to mimic preconditioning (Fig. 1). All interventions were evaluated in both diabetic and 
non-diabetic hearts.
We conducted a dose-response correlation and two experimental series: an infarct size study and a mito-
chondrial respiratory and function study. We did not evaluate infarct size in the Sham groups as it is known to be 
negligible26 and without importance for the conclusions of the study.
Following isolation, hearts were allowed to stabilize for 30–40 minutes depending on the type of intervention. 
Subsequently, they received 40 minutes global no-flow ischemia followed by 30 minutes (experimental series II) 
or 120 minutes (experimental series I) of reperfusion. After 30 minutes of reperfusion in experimental series II, 
the left ventricular muscle was quickly removed and divided into three parts. One part was immediately stored 
in an ice-cold relaxing solution (BIOPS, composition in mM: 2.77 CaK2 EGTA, 7.23 EGTA, 20 taurine, 6.56 
MgCl2, 5.77 ATP, 15 phosphocreatine, 0.5 dithiothreitol and 50 4-morpholineethanesulphonic acid; pH 7.1) for 
the measurements of mitochondrial respiratory capacity and mitochondrial fatty acid oxidation. The remaining 
parts were quickly frozen in liquid nitrogen and stored at −80 °C for later analyses, including mitochondrial 
enzymatic activities and protein content.
In the human study, patients were recruited after project information and giving written consent. The fol-
lowing criteria led to exclusion: age >85 years, atrial fibrillation, ejection fraction <30% or CKMB or Troponin 
T elevation within 2 weeks. Following excision of the right atrial appendage it was immediately immerged in 
oxygenated Krebs-Henseleit buffer (pH 7.35–7.45, room temperature) and transported to the laboratory. After 
suspension in the superperfused atrial strip myograph, each working trabecula was randomized to one of the 
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following groups: (I) IR-injured trabeculae (IR group), (II) IR-injured trabeculae treated with IPC by 10 minutes 
of anoxia followed by 10 minutes of reperfusion prior to sustained anoxia (IPC group) and (III) IR-injured trabec-
ulae co-perfused with 5 mM DiMAL for 20 minutes prior to sustained anoxia (DiMAL group) (Fig. 2).
Analysis of blood glucose and plasma metabolites. Prior to isolation of the heart pre-anesthetic 
fasting blood samples were taken by tail-vein bleeding for measurements of fasting blood glucose (FreeStyle 
Precision, Abbott Diabetes Care, Copenhagen, Denmark) and plasma insulin as previously described22. A fasting 
blood glucose measurement above 7 mmol/L was used to define the diabetic status. Samples for insulin meas-
urements were collected in heparinized tubes (approximately 400uL) and centrifuged (5000 RPM for 1 minute 
at ambient temperature). The supernatant was stored at −80 °C before analysis with a hypersensitive rat insulin 
ELISA kit (DRG instruments, Marburg, Germany). Serum total-cholesterol, triglycerides and free fatty acids 
were measured in 1 ml blood samples drawn from the abdominal aorta immediately before excision of the heart. 
Preparations included centrifugation (3500 RPM for 10 minutes at −4 °C), collection of the supernatant and stor-
age at −80 °C until analysis on a Cobas Integra Analyzer (Roche Diagnostics, Rotkreuz, Switzerland).
Isolated heart preparation. Isolated perfused rat hearts (Langendorff perfusion) were prepared as previ-
ously described27. Rats were anesthetized by a subcutaneous injection with a mixture of Dormicum (midazolam, 
0.5 mg (kg body weight−1); Matrix Pharmaceuticals, Herlev, Denmark) and Hypnorm (fentanyl citrate, 0.158 mg 
(kg body weight−1 and fluanisone, 0.5 mg (kg body weight−1)).
A tracheotomy was performed and the rat was connected to a rodent ventilator (Ugo Basile 7025 rodent venti-
lator, Comerio, Italy) and ventilated at 60 breaths/minute with a tidal volume of 3 mL. Subsequently, a laparotomy 
Figure 1. Study design of the isolated rat heart study. An overview of the two experimental series of the isolated 
rat heart study including subgroups and perfusion protocols. IR: Ischemia reperfusion, DiMAL: Dimethyl 
Malonate, VF: Ventricular fibrillation.
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and thoracotomy were performed and a bolus of 1000 IU/kg heparin (Leo Pharma, Ballerup, Denmark) was 
administrated through the femoral vein. The ascending aorta was cannulated in situ and retrograde perfusion 
of the heart was commenced at a constant pressure of 80 mmHg with an oxygenated (95% O2 and 5% CO2) 
Krebs Henseleit buffer (KHB: composition in mM: NaCl 118.5, KCl 4.7, NaHCO3 25.0, glucosemonohydrate 11.0, 
MgSO4·7H2O 1.2, CaCl2 2.4 and KH2PO4 1.2). The heart was excised under continuous perfusion and mounted 
in an isolated perfused heart system (IH-SR type844/1; HSE, March-Hugstetten, Germany) where temperature 
is kept constant at 37 °C. An intraventricular balloon (Size 7, HSE, March-Hugstetten, Germany) was inserted in 
the left ventricle after removing the left atrial appendage and the intraventricular balloon volume was adjusted 
to a left ventricular end-diastolic pressure of 4–8 mmHg to simulate preload. Coronary flow was monitored con-
tinuously using an inline flow probe (Type 2.5SB, Transonic System Inc., Ithaca, NY, USA). Data was digitally 
converted (DT9804; Data Translation. Marlboro, MA, USA) and stored using Notocord Hem software (version 
2.0, Notocord systems, Croissy sur Seine, France).
Atrial strip model. Isolated atrial trabeculae were prepared as previously described28. Patients undergo-
ing CABG or valve-replacement surgery were enrolled in the study. Within 20 minutes of excision of the atrial 
appendage, atrial trabeculae were tied by a suture (4.0 silk) in each end, excised from the remaining atrial append-
age and mounted in the atrial strip myograph. Sutures are connected to a force transducer and a fixed hook.
The atrial trabeculae (length ranging between 5 and 10 mm and diameter ranging between 400–600 µm) were 
submerged into 37 °C Krebs-Henseleit buffer oxygenated with 95% O2 and 5% CO2 to maintain pH between 7.35 
and 7.45. The isolated trabeculae were stimulated with 1 Hz by platinum electrodes connected to stimulators 
(Harvard Apparatus, amplitude 30 V, duration 1 ms) during stabilization and reoxygenation. Simulated ischemia 
was established by increased pacing (3 Hz) and changing to a hypoxic buffer (composition in mM: NaCl 118.5, 
KCl 4.7, NaHCO3 25.0, choline chloride 14.0, MgSO4·7H2O 1.2, CaCl2 2.4 and KH2PO4 1.2), which was deoxy-
genated with 95% N2 and 5% CO2. After mounting the trabeculae in the organ baths, all trabeculae were stretched 
Figure 2. Study design of human study. An overview of the experimental series of the study including 
subgroups and perfusion protocols. IR: Ischemia reperfusion, IPC: Ischemic preconditioning, DiMAL: 
Dimethyl Malonate, AFLI: Atrial fibrillation.
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passively to a pretension of 0.5 g and left to stabilize for 30 minutes. Subsequently pretension was increased to 
0.75 g for additional 45 minutes of stabilization.
Infarct size. At the end of perfusion in experimental series I of the isolated rat heart study, hearts were fro-
zen at −80 °C, sliced (1.5 mm thick) and vital stained with 1% 2,3,5-triphhenyltetrazoliumchloride (Merck, 
Darmstadt, Germany) for 3 minutes at 37 °C to delineate areas of infarction. The stained heart slices were pre-
served in formaldehyde (10%) for 24–48 hours and then scanned using a flatbed scanner (Epson Perfection V600, 
Epson, Suwa, Japan) and weighed (Mettler-Toledo level balances, Mettler-Toledo, USA)16. Area-at-risk and 
area-of-infarction (infarct size) were assessed using image analysis software (ImageJ, National Institute of Health, 
USA) and weighted with the wet weight of the individual slices. Finally, infarct size/area-at-risk (IS/AAR) ratio 
was calculated. An observer blinded to treatment and disease groups analyzed the data.
Contractile force assessment. Contractile force was measured using a force transducer and data was 
digitally converted (DT9804; Data Translation. Marlboro, MA, USA) and stored using Notocord Hem software 
(version 2.0) (Notocord systems, Croissy sur Seine, France). Contractile force recovery was calculated as a ratio 
of post-ischemic contractile force divided by pre-ischemic contractile force and served as a surrogate marker of 
myocardial IR injury28.
Mitochondrial respiratory capacity. At the end of the perfusion protocol in experimental series II of 
the isolated rat heart study, the left ventricle was quickly divided in two samples during continued perfusion 
for subsequent measurement of mitochondrial respiration and various tissue analyses. In the human study the 
trabeculae were removed and the areas affected by the ligature were discarded. The tissue was stored temporarily 
in a cold (0–4 °C) relaxation buffer (BIOPS; composition in mM: CaK2EGTA 2.77, K2EGTA 7.23, Na2ATP 5.77, 
MgCl2·6H2O 6.56, Taurine 20, Na2Phosphocreatine 15, Imidazole 20, Dithiothreitol 0.5 and MES 50; pH 7.1; kept 
between 0–4 C°) until isolation of the fibers.
Mitochondrial respiration was measured in permeabilized cardiac muscle fibers as previously described16. 
Muscle fibers were dissected free of connective tissue in ice-cold BIOPS buffer using sharp forceps. After dissec-
tion, fibers were placed in ice-cold BIOPS-buffer supplemented with 50 μg·mL−1 Saponin for 30 minutes to ensure 
permeabilization. Fibers were subsequently washed by agitation in ice-cold MiR05-buffer (composition in mM): 
EGTA 0.5, MgCl2·6H2O 3.0, K-lactobionate 60, Taurine 20, KH2PO4 10, HEPES 20, Sucrose 110 and BSA 1 g·L−1; 
pH 7.1) for two times 10 minutes. Muscle fibers were then weighed and transferred to an oxygraph (Oxygraph-2k; 
Oroboros, Innsbruck, Austria) for measurement of glucose supported metabolism (protocol l) and fatty acid sup-
ported metabolism (protocol 2). All measurements were performed as duplicates in hyperoxygenation to avoid 
potential oxygen limitations to respiration. Due to limited tissue available for high-resolution respirometry only 
protocol 1 was applied in the human study.
Protocol 1 (complex I + II-linked respiration): Malate (2 mM) and glutamate (10 mM) were added to evaluate 
state 2 respiration (GM). After addition of ADP (5 mM) state 3 respiration was achieved (GM3). Respiratory 
control ratio (RCR) was calculated as state 3/state 2. Cytochrome c (10 μM) was added to evaluate outer mito-
chondrial membrane integrity (more than 10% increases in respiration lead to exclusion). Subsequently, succinate 
(20 mM) was added to activate complex II during state 3 (GMS3) followed by Oligomycin (2.5 μM) to achieve 
state 4 respiration (4o). Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP) was added to evaluate 
maximal respiratory capacity in a non-coupled state (E). Finally, Rotenone (0.5 μM) and Antimycin A (2.5 μM) 
were added to estimate residual oxygen consumption (ROX).
Protocol 2 (fatty acid oxidation): Malate (2 mM) was added to give fundamental stimulation of complex I 
(state 2 respiration) followed by multiple titrations of Octanoyl-1-carnitine to achieve maximal β-oxidation 
and complex II respiration (MOc). State 3 respiration is achieved by adding ADP (5 mM, MOc3) and finally 
cytochrome c (10 μM) was added to examine outer membrane integrity.
Mitochondrial enzyme activity. Citrate synthase (CS) activity, a key enzyme in the glucose oxidation and 
marker of mitochondrial content, and β-hydroxyacyl-CoA dehydrogenase (HAD) activity, a key enzyme in the 
fatty acid oxidation, were measured in cardiac tissue homogenate by spectrophotometry as previously described29. 
In short, 2–3 mg wet weight of cardiac muscle were homogenized in a TissueLyser (Qiagen, Venlo, Limburg, The 
Netherlands). For CS, the homogenate was diluted 50 times and the conversion of 5.5-dithiobis-(2-nitrobenzoic 
acid) to 5-thiobis-(2-nitrobenzoic acid) was measured at 37 °C spectrophotometrically at 415 nm on an automatic 
analyzer (Cobas 6000, C 501, Roche Diagnostics, Mannheim, Germany). For HAD, the homogenate was diluted 
70 times and changes in NADH at 37 °C were measured spectrophotometrically at 340 nm on an automatic ana-
lyzer (Cobas 6000, C 501, Roche Diagnostics).
Mitochondrial protein content of ETC complexes. Mitochondrial protein content was measured as 
previously described30. In short, the protein homogenates were diluted in Laemmeli buffer and 15 µg of total 
protein from each sample was separated on precast criterion gels (Bio-Rad, Copenhagen, Denmark). After 
electrophoresis, the gel was electrophoretically transferred to a polyvinylidene fluoride (PVDF) membrane. 
The membranes were blocked over night at 4 °C with skim milk diluted in phosphate-buffered saline. The Total 
OXPHOS antibody cocktail (Abcam, ab110413) was used to determine the proteins of interest and set to incubate 
at room temperature for 1 hour followed by incubation with horseradish peroxidase-conjugated secondary anti-
bodies (Dako, Glostrup, Denmark). Visualization of antibody-specific labeling bands were revealed with activa-
tion with enhanced chemiluminescence Western blotting detection system (ECL, GE Healthcare, Little Chalfont, 
UK) and a CCD camera (LAS 4000, GE Healthcare). We quantified intensities of each specific band obtained by 
chemiluminescence using Image Quant TL software (GE Healthcare, USA) and normalized to the entire UV 
intensity of the corresponding sample representing the total protein content on the membrane.
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Complex II activity. Frozen tissue was homogenized in a PBS buffer supplemented with protease inhibi-
tors and prepared for complex II activity measurements using a Complex II Enzyme activity assay kit (Abcam, 
ab109908). Colorimetric measurements were achieved using PheraStar FS (BMG Labtech, Aylesbury, UK).
Myocardial interstitial concentrations of succinate. Myocardial interstitial concentration of succinate was meas-
ured in the 0.6 mM DiMAL group in non-diabetic and diabetic rats by microdialysis as previously described27. A 
microdialysis probe (membrane length 4 mm, cut-off 6 Da; AgnTho’s, Lidingoe, Sweden) was inserted into the free 
wall of the left ventricle. The microdialysis probe was continuously perfused at a flow speed of 1 μL/minutes. with 
Krebs-Henseleit buffer solution deoxygenated with 95% N2 and 5% CO2. Following the implantation, a 20 min-
utes stabilization period was allowed for the metabolites to reach equilibrium in the perturbed tissue. Samples 
were collected at 10 minutes intervals and later analyzed by liquid chromatography and mass spectrometry.
Statistical analysis. All results are expressed as mean ± SD. Non-diabetic and diabetic groups were com-
pared by two-way ANOVA. Comparison between baseline characteristics of patients with and without diabetes 
was done by t-test. Between groups comparison was performed using one-way ANOVA followed by a Bonferroni 
post-hoc analysis when appropriate. We used Prism, version 6.0 (GraphPad Software, La Jolla, CA, USA) for all 
statistical analyses. P < 0.05 was considered statistically significant.
Results
Exclusions. Isolated rat heart study. A total of 4 rats (all non-diabetic) were excluded prior to enrolment in 
the study (Fig. 1). Three rats were excluded due to ventricular fibrillation in the stabilization period and one rat 
due to unsuccessful surgical procedure. Complete datasets were achieved from the remaining rats.
Human study. In the human study 5 patients were excluded after giving written consent due to small atrial 
tissue sample sizes (Fig. 2). 10 patients were allocated to protocol optimization and dose/response correlation. 
33 patients were enrolled in the study and 12 patients were excluded because the fibers did not reach sufficient 
hemodynamic performance of 0.5 g of contractility at the end of stabilization28.
Baseline characteristics. Isolated rat heart study. Bodyweight, heart weight, fasting blood glucose levels 
and biochemical characteristics are summarized in Table 1. Body and heart weight did not differ between dia-
betic and non-diabetic rats. Fasting blood glucose was significantly higher in diabetic groups compared to the 
respective non-diabetic groups. Diabetic rats in the DiMAL 0.1 mM groups had significantly higher glucose levels 
than the other diabetic groups. We found no significant differences between all other diabetic and non-diabetic 
disease groups.
The diabetic groups had significant elevation in the biochemical variables, including insulin, cholesterol, tri-
glycerides and free fatty acids (Table 1), compared to their respective non-diabetic groups. S-cholesterol was 
Type Non-diabetic Non-diabetic Non-diabetic Diabetic Diabetic Diabetic
Group IR (n = 8)
DiMAL 0.1 mM 
(n = 8)
DiMAL 0.6 mM 
(n = 8) IR (n = 9)
DiMAL 0.1 mM 
(n = 8)
DiMAL 0.6 mM 
(n = 8)
Characteristics of the ZDF rat model
Infarct size study
Body weight (BW), g 402 ± 22 405 ± 30 404 ± 25 403 ± 37 407 ± 28 387 ± 21
Heart weight (HW), g 1.18 ± 0.15 1.20 ± 0.10 1.23 ± 0.12 1.23 ± 0.11 1.18 ± 0.07 1.19 ± 0.05
HW/BW ratio 0.29 ± 0.03 0.30 ± 0.02 0.30 ± 0.02 0.31 ± 0.03 0.29 ± 0.02 0.31 ± 0.02
B-glucose, mmol/L 4.7 ± 0.4 5.5 ± 0.7 4.7 ± 0.3 15.0 ± 4.1 Ŧ# 24.7 ± 1.9 Ŧ 12.8 ± 3.4 Ŧ#
P-insulin, pmol/L 44.2 ± 18.1 47.9 ± 9.7 41.2 ± 15.4 88.0 ± 27.6 Ŧ 89.4 ± 21.7 Ŧ 82.7 ± 14.3 Ŧ
S-total cholesterol, mmol/L 2.17 ± 0.20 2.46 ± 0.27 2.29 ± 0.40 4.11 ± 0.72 Ŧ# 5.18 ± 077 Ŧ 4.00 ± 0.46 Ŧ#
S-triglyceride, mmol/L 0.88 ± 0.52 0.78 ± 0.32 0.97 ± 0.39 9.81 ± 1.50 Ŧ 8.87 ± 0.53 Ŧ 9.90 ± 0.56 Ŧ
S-free fatty acids, mmol/L 1.70 ± 1.34 1.80 ± 0.78 1.71 ± 0.58 6.14 ± 0.56 Ŧ 5.83 ± 1.49 Ŧ 5.21 ± 1.77 Ŧ
Mitochondrial function study
Type Non-diabetic Non-diabetic Non-diabetic Non-diabetic Diabetic Diabetic Diabetic Diabetic
Group Sham (n = 8) IR (n = 8) DiMAL 0.1 mM (n = 8)
DiMAL 0.6 mM 
(n = 7) Sham (n = 8) IR (n = 9)
DiMAL 0.1 mM 
(n = 8)
DiMAL 0.6 mM 
(n = 8)
Body weight (BW), g 413 ± 26 397 ± 18 400 ± 34 423 ± 31 408 ± 46 370 ± 38 390 ± 19 392 ± 42
B-glucose, mmol/L 4.8 ± 0.2 5.0 ± 0.4 5.1 ± 0.5 4.7 ± 0.3 12.5 ± 3.1 Ŧ# 13.0 ± 2.7 Ŧ# 24.2 ± 4.0 Ŧ 11.9 ± 1.8 Ŧ#
P-insulin, pmol/L 47.2 ± 16.2 36.4 ± 12.9 49.4 ± 10.1 46.3 ± 12.1 82.0 ± 24.8 Ŧ 75.3 ± 18.0 Ŧ 74.3 ± 18.0 83.1 ± 32.8 Ŧ
S-total cholesterol, mmol/L 2.19 ± 0.15 2.23 ± 0.18 2.09 ± 0.57 2.43 ± 0.14 4.32 ± 0.32 Ŧ 3.83 ± 0.75 Ŧ# 4.95 ± 0.95 Ŧ 4.04 ± 0.27 Ŧ#
S-triglyceride, mmol/L 0.94 ± 0.44 0.94 ± 0.37 0.87 ± 0.21 1.18 ± 0.42 9.97 ± 0.77 Ŧ# 10.14 ± 0.53 Ŧ# 8.37 ± 0.96 Ŧ 9.99 ± 0.81 Ŧ#
S-free fatty acids, mmol/L 1.73 ± 0.72 1.50 ± 0.90 1.83 ± 0.51 2.03 ± 1.14 5.92 ± 0.78 Ŧ 5.18 ± 2.07 Ŧ 4.71 ± 1.45 Ŧ 5.063 ± 1.51 Ŧ
Table 1. Characteristics of the ZDF rat model. Data are mean ± SD. Ŧ P < 0.05 grouped diabetic rats (fa/fa) 
compared to their grouped age-matched controls. #P < 0.05 diabetic group vs. diabetic DiMAL 0.1 mM.
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significantly elevated in DiMAL 0.1 mM compared to other diabetic groups. Between all other groups within the 
diabetic and non-diabetic disease groups, we found no significant differences.
Human study. We found no differences between patients with and without diabetes on age, BMI, total choles-
terol, LDL-, HDL-cholesterol or triglyceride (Table 2). We found significantly higher HbA1c levels in patients 
with diabetes compared to patients without diabetes (8.7 ± 1.0 vs. 6.2 ± 0.6 mmol/L of HbA1c, P < 0.05). All 
patients with diabetes received antihypertensive and statin treatment, compared to only 58% and 25% in patients 
without diabetes (p < 0.05).
Infarct size. Isolated rat heart study - Dose-response relationship. The dose-response relationship of DiMAL 
treatment in non-diabetic rat hearts revealed a u-shaped relationship between dose and infarct size. Infarct size 
was reduced in the 0.1 mM DiMAL group compared to IR alone (54 ± 6% vs. 69 ± 6% of LV, p < 0.05) (Fig. 3). 
DiMAL concentrations of 0.05 mM, 0.3 mM and 0.6 mM did not provide reductions in infarct size compared to 
IR (64 ± 14%, 63 ± 16% and 73 ± 13% vs. 69 ± 6%).
Isolated rat heart study - infarct size. Infarct size following IR did not differ statistically significantly in diabetic 
compared to non-diabetic rats (79 ± 8% and 69 ± 6%, p = 0.07) (Fig. 3). In non-diabetic animals, DiMAL 0.1 mM 
reduced infarct size compared to the IR group (55 ± 7% vs. 69 ± 6%, p < 0.05). DiMAL 0.6 mM yielded no pro-
tection (73 ± 13% and 69 ± 6%, p = 0.71) (Fig. 3). In diabetic hearts, DiMAL 0.1 mM treatment did not reduce 
infarct size compared to the IR group (68 ± 8% and 79 ± 8%, p = 0.14) whereas DiMAL 0.6 mM yielded signifi-
cant protection (64 ± 13% vs. 79 ± 8%, p < 0.05).
Contractile force recovery. Human study - Dose-response relationship. The dose-response relationship 
of DiMAL treatment in non-diabetic human atrial trabeculae showed that a concentration of 5 mM yielded the 
largest improvement in contractile force recovery compared to IR alone (54 ± 34% vs. 24 ± 6% of contractile force 
recovery, p = 0.67) (Fig. 4). Reduction of DiMAL concentration to 3 mM or an increment to 10 mM attenuated or 
Patients characteristics
Type
Patient without 
diabetes
Patient with 
diabetes p value
(n = 12) (n = 9)
Age, year (mean ± SD) 64 ± 9 63 ± 7 0.75
Male gender, n (%) 11 (92) 8 (77) 0.78
Smoker, n (%) 1 (8) 1 (11) 0.78
Former smoker, n (%) 7 (58) 6 (67) 0.47
BMI, kg/m2 n (mean ± SD) 27.1 ± 4.4 30.0 ± 4.0 0.15
HbA1C, mmol/L (mean ± SD) 6.2 ± 0.6 8.7 ± 1.0 <0.05
Total cholesterol, mmol/L (mean ± SD) 4.0 ± 1.0 4.3 ± 1.4 0.63
LDL, mmol/L (mean ± SD) 2.2 ± 0.7 2.5 ± 1.1 0.41
HDL, mmol/L (mean ± SD) 1.1 ± 0.3 0.9 ± 0.2 0.30
Triglyceride, mmol/L (mean ± SD) 1.7 ± 1.0 1.8 ± 0.5 0.70
Statin therapy, n (%) 3 (25) 9 (100) <0.05
Antihypertensive therapy, n (%) 7 (58) 9 (100) <0.05
Table 2. Patient characteristics. Data are mean ± SD.
Figure 3. Isolated rat heart study – Dose-response relationship and infarct size. Dose-response relationship 
showing the effect of DiMAL on infarct size (IS) as a percentage of area at risk (AAR) in non-diabetic rat hearts 
(a) and IS/AAR of different intervention groups in non-diabetic and diabetic ZDF rat hearts (b). IR: Ischemia 
reperfusion, DiMAL: Dimethyl Malonate. Data are the mean ± SD. *P < 0.05 between indicated groups.
8Scientific RepoRtS |        (2020) 10:10344  | https://doi.org/10.1038/s41598-020-67247-4
www.nature.com/scientificreportswww.nature.com/scientificreports/
abolished contractile force recovery improvements, respectively, compared to IR alone (35 ± 1%, 22 ± 10% and 
24 ± 6% of contractile force recovery, p > 0.99).
Human study. Contractile force did not differ between patients without and with diabetes (ANOVA p > 0.99). 
IPC improved contractile force recovery in trabeculae from patients without diabetes compared to trabeculae 
undergoing IR alone (43 ± 12% vs. 23 ± 13%, p < 0.05) (Fig. 4). DiMAL 5 mM yielded the same improvement 
in non-diabetic trabeculae (43 ± 13% vs. 23 ± 13%, p < 0.05). IPC in trabeculae from patients with diabetes 
improved contractile force recovery compared to IR and DiMAL (51 ± 15% vs. 21 ± 8% and 29 ± 16%, p < 0.05). 
In contrast, DiMAL did not significantly affect contractile force recovery compared to IR in diabetic trabeculae 
(29 ± 16% and 21 ± 8%, p = 0.83).
Mitochondrial respiratory capacity. Isolated rat heart study. Diabetes reduced mitochondrial respi-
ration capacity compared to non-diabetic hearts as evaluated by GM, GM3, GMS3 and RCR (Fig. 5, ANOVA: 
p = 0.02, p = 0.002, p = 0.004 and p = 0.04, respectively). DiMAL 0.1 mM increased State 2 respiration (GM) com-
pared to DiMAL 0.6 mM but not compared to IR in non-diabetic hearts (41.6 ± 8.7 vs. 28.5 ± 5.3 and 33.9 ± 7.9 
pmol O2/(s*mg), p < 0.05 and p = 0.25). We observed no other differences in state 2 respiration in either the 
non-diabetic or the diabetic group. State 3 complex I-linked respiration capacity (GM3) was higher in both 
the Sham and DiMAL 0.1 mM groups than in the DiMAL 0.6 mM group in non-diabetic hearts (157.4 ± 26.5 
and 140.0 ± 35.3 vs. 81.8 ± 42.4 pmol O2/(s*mg), p < 0.01 and p < 0.05). IR alone numerically reduced the res-
piration compared to Sham (157.4 ± 26.5 vs. 112.3 ± 27.0 pmol O2/(s*mg), p = 0.09). State 3 complex I- and 
II-linked respiration (GMS3) was higher in non-diabetic Sham hearts than in non-diabetic hearts exposed 
to IR, DiMAL 0.1 mM, DiMAL 0.6 mM as well as in the diabetic Sham group (283.5 ± 53.6 vs. 207.6 ± 42.6, 
211.0 ± 44.1, 213.3 ± 48.0 and 198.8 ± 50.0 pmol O2/(s*mg) (p < 0.05), respectively). The RCR was higher in the 
Sham groups compared to any of the intervention groups regardless of the presence of diabetes. No differences 
were observed between intervention groups in state 4o (Fig. 5), non-coupled state E with FCCP (Fig. 5) or ROX 
(data not shown).
Human study. State 2 respiration (GM) and state 3 complex I-linked respiration (GM3) did not differ between 
trabeculae from patients with and without diabetes and was not affected by IPC or DiMAL (Fig. 6). Also, State 
3 complex I + II linked respiration (GMS3) further increased the level of respiration in all groups but with no 
differences between trabeculae from patients with and without diabetes or between interventions. Consistent 
with this finding, we observed no change in RCR by any intervention. State 4o, non-coupled state E with FCCP 
and ROX were similar in all intervention groups and between trabeculae from patients with and without diabetes 
(ROX data not shown).
Mitochondrial fatty acid oxidation. Isolated rat heart study. Diabetes reduced mitochondrial respira-
tion capacity compared to non-diabetic hearts as evaluated by MOc3 and RCR (Fig. 7, ANOVA: p = 0.007 and 
p = 0.02). All interventions reduced mitochondrial fatty acid oxidation compared to the non-diabetic sham group. 
(MOc: Sham 50.3 ± 6.7 vs. IR 35.4 ± 5.2 vs. DiMAL 0.1 mM 37.7 ± 10.2 vs. DiMAL 0.6 mM 32.2 ± 10.6 pmol O2/
(s*mg) (p < 0.05); MOc3: Sham 106.6 ± 14.0 vs. IR 75.5 ± 12.0 vs. DiMAL 0.1 mM 58.2 ± 21.6 vs. DiMAL 0.6 mM 
73.6 ± 30.2 pmol O2/(s*mg)) (p < 0.05) (Fig. 7). Pre-ischemic inhibition by DiMAL 0.1 mM reduced state 3 respi-
ration (MOc3) in diabetic hearts compared to the Sham group (Sham 80.3 ± 14.4 vs. 50.1 ± 5.7 pmol O2/(s*mg)). 
RCR was reduced in the DiMAL 0.1 mM group in both non-diabetic (DiMAL 0.1 mM 1.52 ± 0.21 vs. Sham 
2.15 ± 0.34 vs. IR 2.03 ± 0.23 vs. DiMAL 0.6 mM 2.23 ± 0.27, (p < 0.05)) and diabetic hearts (DiMAL 0.1 mM 
1.52 ± 0.23 vs. Sham 2.03 ± 0.14 vs. IR 1.88 ± 0.23 vs. DiMAL 0.6 mM 1.95 ± 0.16, (p < 0.05)). Finally, diabetes 
was associated with an overall decrease in respiration as observed by state 3 respiration and RCR (ANOVA: 
p = 0.007 and 0.02).
Figure 4. Human study – Dose-response relationship and contractile force recovery. Dose-response 
relationship between DiMAL and contractile force recovery in non-diabetic human atrial trabeculae (a) and 
contractile force recovery of non-diabetic and diabetic human atrial trabeculae given as a ratio of contractile 
force in the reperfusion compared to the pre-ischemic value (b). IR: Ischemia reperfusion, DiMAL: Dimethyl 
Malonate, IPC: Ischemic preconditioning. Data are mean ± SD. *P < 0.05 between indicated groups. P-values at 
the top indicate overall effect of diabetes and interventions by two-way ANOVA, respectively.
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Mitochondrial enzyme activity. Isolated rat heart study. No overall difference in CS activity was seen 
between the diabetic and non-diabetic group. Citrate synthase (CS) activity did not differ between groups in the 
non-diabetic hearts (Sham 196 ± 61 and IR 182 ± 25 and DiMAL 0.1 mM 201 ± 61 and DiMAL 0.6 mM 212 ± 85 
µmol/min/g (p = 0.82)) or the diabetic hearts (Sham 198 ± 44 and IR 196 ± 66 and DiMAL 0.1 mM 201 ± 44 and 
DiMAL 0.6 mM 194 ± 69 µmol/min/g (p = 0.99) (Fig. 8). β-Hydroxyacyl-CoA dehydrogenase (HAD) activity was 
not different between intervention groups in either the non-diabetic (Sham 187 ± 55 and IR 168 ± 26 and DiMAL 
0.1 mM 190 ± 65 and DiMAL 0.6 mM 201 ± 80 µmol/min/g) or diabetic hearts (Sham 230 ± 64 and IR 240 ± 81 
and DiMAL 0.1 mM 239 ± 63 and DiMAL 0.6 mM 236 ± 83 µmol/min/g). Diabetic hearts had a higher HAD 
activity than non-diabetic hearts (ANOVA p < 0.05).
Figure 5. Isolated rat heart study - Mitochondrial respiratory capacity. Representative graph of mitochondrial 
respiratory capacity from a Sham heart. Below mitochondrial respiratory capacity. GM, state 2 respiration with 
glutamate + malate (a); GM3, state 3 respiration with glutamate and malate (b); GMS3, state 3 respiration with 
glutamate, malate and succinate (c); 4o, state 4 respiration with oligomycin (d); FCCP, non-coupled state by 
FCCP (e); RCR with complex I-linked substrates (f). Data are mean ± SD. *P < 0.05 between indicated groups. 
P-values at the top indicate overall effect of diabetes and interventions by two-way ANOVA, respectively.
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Mitochondrial protein content of ETC complexes and complex II activity. The protein content 
of the mitochondrial ETC complexes I-V in cardiac muscle did not differ between groups (Fig. 8) or between 
non-diabetic and diabetic cardiac tissue. Complex II activity in cardiac muscle was similar in all groups (Fig. 8).
Interstitial succinate concentration. Diabetic IR hearts had statistically non-significantly lower succinate 
concentration than non-diabetic IR hearts (58 ± 14 vs. 90 ± 35 vs. µmol/L, p = 0.30) (Fig. 8). After 60 minutes 
of ischemia DiMAL reduced succinate concentrations in the non-diabetic group (90 ± 35 vs. 33 ± 42 µmol/L, 
p < 0.05). DiMAL also reduced interstitial succinate concentration in diabetic hearts but the difference was not 
statistically significant (43 ± 18 vs. 58 ± 14 µmol/L, p > 0.99).
Figure 6. Human study - Mitochondrial respiratory capacity. Representative graph of mitochondrial 
respiratory capacity from an IR heart trabecula. Below mitochondrial respiratory capacity. GM, state 2 
respiration with glutamate + malate (a); GM3, state 3 respiration with glutamate and malate (b); GMS3, state 
3 respiration with glutamate, malate and succinate (c); 4o, state 4 respiration with oligomycin (d); FCCP, non-
coupled state by FCCP (e); RCR with complex I-linked substrates (f). Data are mean ± SD. *P < 0.05 between 
indicated groups. P-values at the top indicate overall effect of diabetes and interventions by two-way ANOVA, 
respectively.
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Discussion
The main finding of the present study is that inhibition of the SDH by administration of DiMAL protects the heart 
from IR injury in non-diabetic and diabetic animals. However, diabetes seems to reduce the sensitivity to DiMAL 
such that an increased dose is required to elicit a cardioprotective response. The DiMAL induced cardioprotection 
was associated with an improvement of post-ischemic mitochondrial function in non-diabetic animals but not in 
diabetic animals. Diabetes per se compromised mitochondrial respiration capacity, reflecting that mitochondrial 
dysfunction may explain reduced sensitivity to cardioprotective strategies in experimental models of diabetes. At 
a dose optimized through a dose-response experiment, a cardioprotective effect of DiMAL was present in human 
cardiac tissue from patients without diabetes, while cardiac tissue from patients with diabetes was not protected 
by the administered doses of DiMAL. In contrast to our experimental findings, mitochondrial function was not 
compromised in human cardiac tissue from diabetes patients and the absent effect of DiMAL was not associated 
with mitochondrial respiratory capacity.
Our results support previous findings of a cardioprotective effect by DiMAL11,31,32. SDH inhibition has become 
an attractive target in pharmacologic conditioning because it may interact with central mechanisms underlying 
IR injury11. Complex I is the major source of mitochondrial ROS production. During ischemia, the purine nucle-
otide cycle (PNC)11 and the MAS27 supply fumarate to Complex II, which acts in reverse to reduce fumarate to 
succinate. At reperfusion, oxygen supply is restored, and Complex II rapidly metabolizes the excess succinate 
in its forward direction to fumarate. However, a delay in the subsequent steps prevents further Complex III-V 
metabolism, when the mitochondrial membrane potential increases. As a consequence, electrons are forced in 
a reverse direction through Complex I generating large amounts of ROS. Excessive ROS production ultimately 
cause opening of the mitochondrial permeability pore complex and cell death9.
DiMAL is a competitive inhibitor of the SDH that binds to the succinate site of the enzyme15. DiMAL can be 
administrated prior to index ischemia to reduce succinate accumulation11 or during early reperfusion to inhibit 
succinate oxidation thereby limiting reverse electron transport and ROS production32. Our data demonstrate 
that pre-ischemic administration of DiMAL, mimicking preconditioning, is cardioprotective both in rats and 
in human cardiac tissue with an efficacy comparable to IPC. Remote IPC, postconditioning, hypothermia and 
cyclosporine A can induce the same level of cardioprotection as DiMAL33,34. The additive effect of hypothermia 
and DiMAL on infarct size was protective by distinct mechanisms. It is unknown if remote IPC, postconditioning 
or cyclosporine A modifies ROS production by attenuation of succinate production. Our data showed that the 
succinate/ROS pathway does not seem to be an inherent part of IPC, since IPC does not inhibit succinate accu-
mulation during ischemia16,27,35 or succinate oxidation during early reperfusion27,36. These findings suggest that a 
Figure 7. Isolated rat heart study - Mitochondrial fatty acid respiratory capacity. Summarized data of 
mitochondrial fatty acid respiratory capacity in each respiratory state. MOc, state 2 respiration with malate and 
octanoyl-l-carnitine; MOc3, state 3 respiration with malate and octanoyl-l-carnitine; RCR with fatty acids. Data 
are the mean ± SD. *P < 0.05 between indicated groups. P-values at the top indicate overall effect of diabetes 
and interventions by two-way ANOVA, respectively.
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combination of different therapeutic approaches could further protect against IR injury during acute myocardial 
infarction.
We found that an increased concentration of DiMAL was needed to reduce infarct size in diabetic compared 
to non-diabetic animals. This might be caused by changes in the amount or activity of SDH, since DiMAL is a 
competitive inhibitor of SDH. We did not observe any change in protein content of any of the complexes of the 
ETC or differences in complex II activity between groups. The finding indicates that the need for higher concen-
tration of DiMAL may be caused by factors other than protein content and complex II activity, e.g. metabolic 
rate control or substrate selection beyond the mechanisms traditionally claimed to explain the glucose-fatty-acid 
cycle37. Using dosages optimized to non-diabetic trabeculae, we found no protection by DiMAL in patients with 
diabetes. The dosage used in human tissue was chosen from the dose-response relationship in non-diabetic tissue 
and not customized to the diabetic phenotype. The optimized dosage for tissue from patients without diabetes 
was 10 fold higher than in the experimental setting. This is due to difference in drug delivery. In the isolated 
hearts DiMAL was delivered directly though the coronary vessels, whereas the atrial trabeculae were superper-
fused, demanding a higher concentration to achieve effect. Taking the experimental data into consideration, it 
seems plausible that the dosage was insufficient because diabetic animals needed a higher dose than non-diabetic 
animals to achieve protection. Due to low inclusion rates of patients with diabetes, it was not possible to evaluate 
the effect of a higher dosage in the current study, so we cannot exclude that a higher threshold might be pres-
ent in humans as previously demonstrated in the diabetic rats38. Our data suggest that the therapeutic window 
for SDH inhibition is narrow and this may be a translational challenge. We found that even small changes in 
Figure 8. Isolated rat heart study - Mitochondrial enzyme activity. Enzyme activity of citrate synthase (CS) and 
β-hydroxyacyl-CoA dehydrogenase (HAD) (a,b). Below protein content of individual electron transport chain 
complex I-V in non-diabetic (c) and diabetic (d) heart tissue. At the bottom Complex II activity in non-diabetic 
and diabetic tissue (e) and interstitial succinate concentrations (f). IR: Ischemia reperfusion, DiMAL: Dimethyl 
malonate. Data are the mean ± SD. *P < 0.05 between indicated groups. P-values at the top indicate overall 
effect of diabetes and interventions by two-way ANOVA, respectively.
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concentrations of DiMAL could abrogate the protection, supporting previous observations in mice that revealed 
a toxic effect of DiMAL on hemodynamic performance under normoxic conditions31. The respiratory capac-
ity of complex I was severely compromised by the high DiMAL dosage in non-diabetic rats (DiMAL 0.6 mM) 
reflecting the narrow therapeutic window of DiMAL. The deleterious effect may be explained by an irreversible, 
detrimental effect of combining excessive SDH blockade with IR injury, which may inhibit restoration of normal 
respiration during reperfusion. No improvement in mitochondrial respiration was observed in human trabeculae 
treated with DiMAL or IPC indicating that cardioprotection may be achievable without measurable modulation 
of post-ischemic mitochondrial function.
Preserved post-ischemic mitochondrial function is important for cellular function and survival9,39. Our data 
confirmed that diabetes has an inherent deleterious effect on overall mitochondrial respiration in our experimen-
tal setting, which adds to the impaired respiratory capacity following ischemia. We found that administration of 
0.1 mM DiMAL to non-diabetic hearts tended to improve complex I-linked respiration reflecting reduced injury 
to the complex. This improvement in complex I-linked respiration correlates with the current hypothesis that 
DiMAL limits succinate accumulation, reverses electron transport to complex I and ROS-mediated injuries11.
DiMAL reduced accumulation of interstitial succinate during ischemia in non-diabetic and diabetic rat hearts. 
Diabetic hearts seemed to have an inherent ability to reduce succinate accumulation compared to non-diabetic 
hearts. Reduced succinate accumulation during an ischemic event has previously been reported to provide car-
dioprotection16. We found no correlation between reduced succinate accumulation and cardioprotection since 
IR exposed diabetic hearts and DiMAL treated non-diabetic hearts did not have lower infarct sizes compared to 
non-diabetic IR hearts. The missing correlation between succinate buildup during ischemia and cardioprotection 
has previously been reported in the setting of ischemic preconditioning40,41, so the role of succinate in IR injury 
remains unresolved.
Diabetic tissue from rat hearts showed elevated levels of HAD activity corresponding to an elevated fatty acid 
metabolism possibly caused by a reduced ability to metabolize glucose. However, ex vivo rat heart fatty acid oxida-
tion was reduced indicating that other steps in the fatty acid metabolism may be impaired in the diabetic hearts. 
IR reduced fatty acid oxidation and treatment with DiMAL did not improve the respiratory capacity in spite of 
its cardioprotective effect. This finding may simply reflect that the isolated rat hearts only received glucose during 
the perfusion protocol or that fatty acid metabolism may be less important compared to glucose metabolism in 
the protection against IR injury.
CS activity did not differ between non-diabetic and diabetic hearts indicating a similar level of mitochondrial 
content. Diabetes can both up- and down-regulate mitochondrial content over the course of disease progres-
sion42. Our findings may suggest that the diabetic disease model had not yet developed major changes in mito-
chondrial content and support that the respiratory findings are mainly driven by changed respiratory capacity 
rather than the number of mitochondria.
The fact that co-morbidities such as diabetes and co-medication including glucose lowering therapy modify 
the sensitivity to cardioprotection and consequently changes the concentration required to elicit cardioprotection 
increases the complexity of applying the concept into clinical use. This challenge is reflected by the discrepant 
findings between our experimental and human studies. This is probably not a specific characteristic for DiMAL 
but for all modulators of the mitochondrial function. Future studies should focus on safe delivery of ETC mod-
ifiers to the target area in the optimal concentration with absent systemic effect. A recent study addressed this 
problem and demonstrated the potential of intracoronary administration of DiMAL in pigs32. While intracoro-
nary administration increases the therapeutic value of the drug, it will most likely be a delicate balance to achieve 
optimal effect without introducing side effects.
An alternative and safer way to modulate mitochondria may be utilization of a physiological inhibitor rather 
than a synthetic inhibitor, which cannot be metabolized in the cell. Oxaloacetate and malate are tricarboxylic 
acid cycle intermediates with strong inhibitory effect on SDH15, similar to that of DiMAL. It may be possible to 
achieve a protective effect by increasing the levels of e.g. oxaloacetate. Protection by oxaloacetate has been tested 
in rats in a focal brain ischemic model with evidence suggesting a neuroprotective effect43. The concept is further 
supported by the possibility to induce cardioprotection through MAS inhibition by aminooxyacetate (AOA) 
during late ischemia16. AOA inhibits the aspartate amino transferase, which uses oxaloacetate as a substrate and it 
is possible that the protection works though upregulation of oxaloacetate16. Finally, short cycles of IPC have been 
shown to increase malate, the precursor to oxaloacetate, indicating a possible involvement of these tricarboxylic 
acid cycle intermediates in the protection of IPC16.
The current study has limitations. First, we used a ZDF rat model to examine the impact of mature diabetes 
on myocardial IR injury. The ZDF rat is mutated in the leptin receptor resulting in a diabetic phenotype similar 
to the human. Because the leptin receptor is defect, the animals have high circulating levels of leptin, which may 
activate protective pathways44. However, the ZDF model is considered a valid model for type 2 diabetes because 
of the similarities with the human phenotype. Second, the baseline characteristics of the animals were consistent 
with a diabetic phenotype similar to humans with elevated fasting blood glucose, insulin, cholesterol, triglycerides 
and FFA. However, compared to previous studies, the animals in the diabetic groups had lower levels of circulat-
ing glucose concentrations22. Only animals randomized to the DiMAL 0.1 mM groups had blood glucose levels 
similar to previous observations22. However, all animals in the diabetic groups had elevated blood glucose and 
insulin levels and a phenotype consistent with a metabolic syndrome. Third, we used an isolated rat heart model 
to evaluate the cardioprotective effects. Isolation of the heart excludes the influence of systemic and humoral fac-
tors during myocardial IR. Our circulation buffer did not contain insulin or FFA and does not resemble normal 
physiology. Fourth, we used permeabilized myocardial fibers for evaluation of mitochondrial respiration. This 
is a validated method to investigate the mitochondria in situ, and seems to be more physiologically correct than 
isolated mitochondria45. Even so, it does not reflect physiological conditions, which may limit the translation 
into the clinical setting. Fifth, tissue from the right atrial trabeculae may not reflect the function, physiology 
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and metabolism of the left ventricle. Nevertheless, similarities between atrial and ventricular tissue have been 
demonstrated46,47 and the right atrial appendage remains the most ethically applicable method to examine human 
myocardium. Tissue was transported from the operating theater to our laboratory in an oxygenated buffer with a 
transport time below 5 minutes. It cannot be excluded that partial hypoxia might affect the tissue prior to suspen-
sion in the atrial strip model. Finally, we acknowledge the lack of insight into ROS production and injury, which 
limits the mechanistic understanding and interpretation of our data.
In summary, pre-ischemic inhibition of the SDH by DiMAL protects the non-diabetic and diabetic rat heart 
from IR injury. The protection can be translated into human cardiac tissue from patients without diabetes and is 
as effective as IPC. In our animal model, mature diabetes alters the metabolic phenotype that resulted in higher 
resistance to SDH inhibition and requirement for a higher dosage to induce cardioprotection. Accordingly, 
DiMAL treatment with an optimized dosage through dose-response correlation did not protect the diabetic 
human myocardium. The protection is associated with improved post-ischemic mitochondrial function in our 
isolated heart model, but not in the human atrial trabeculae. Conceptually, SDH inhibition may provide a phar-
macological target to counteract IR injury. However, synthetic agents have narrow therapeutic range and efficacy 
may be influenced by diabetes.
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